PROTHENA CORPORATION PUBLIC LIMITED COMPANY Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $761.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-03-15
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $761.00K, a 80.26% decline from fiscal 2015.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $3.85M, a 1492.98% increase from fiscal 2014.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $242.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2016-12-31 | $761.00K 10-K · filed 2019-03-15 |
| 2015-12-31 | $3.85M 10-K · filed 2018-02-26 |
| 2014-12-31 | $242.00K 10-K · filed 2017-02-27 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-25 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |